Healthcare
Adlai Nortye Ltd.(ANL)
Live Price
Offline$10.10
-1.56% today
1Y Change
+546.34%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $790.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +31.9%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Adlai Nortye Ltd. (ANL) is a Healthcare stock with a market cap of $790.00M and listed on NASDAQ. The stock last traded around $10.10 and up 546.3% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +31.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +31.9%, free cash flow +35.1% with operating margin -714.0% and ROIC -197.7%. Valuation already assumes a fairly strong business story at price/sales 158.9. Stock Foundry combines ANL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-714.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +31.9%, while operating margin sits near -714.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +1.3% | +1.3% | -19.8% |
2025 Dec 29, 2025 | +0.0% | -17.2% | -20.6% | +262.8% |
2025 Aug 7, 2025 | +0.0% | +0.6% | +12.9% | +12.9% |
Benchmark Edge
ANL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ANL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ANL Max Drawdown
-51.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ANL and SPY.
Company Overview
Adlai Nortye Ltd.
NASDAQ Global Market
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
- Leadership
- Yang Lu
- IPO Date
- Sep 29, 2023
- Employees
- 123
- Street Address
- Ugland House
- Mailing
- Grand Cayman, KY1-1104
- Region
- Grand Cayman, KY
- Reporting Currency
- USD
- Investor Line
- 848 230 7430
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 158.9
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +31.9%
- Free Cash Flow
- +35.1%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -714.0%
- Net Margin
- -710.6%
- ROE
- -414.0%
- ROIC
- -197.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.65
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.